UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth Group (UNH.N) said on Tuesday it will remove AbbVie’s (ABBV.N) blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.